Gln27→Gluβ2‐Adrenergic Receptor Polymorphism in Heart Failure Patients: Differential Clinical and Oxidative Response to Carvedilol |
| |
| Authors: | Rodrigo Troncoso Francisco Moraga Mario Chiong Juan Roldán Roberto Bravo Rodrigo Valenzuela Guillermo Díaz‐Araya Andrea Del Campo Carlos Sanhueza Andrea Rodriguez José Luis Vukasovic Rosemarie Mellado Douglas Greig Pablo F Castro Sergio Lavandero |
| |
| Institution: | 1. FONDAP Center for Molecular Studies of the Cell, Faculty of Chemical and Pharmaceutical Sciences;2. Faculty of Medicine, University of Chile;3. Faculty of Chemistry;4. Clinical Hospital, P. Catholic University of Chile, Santiago, Chile |
| |
| Abstract: | Abstract: We investigated the clinical response of chronic heart failure patients with β2‐adrenergic receptor Gln27→Glu polymorphism treated for 6 months with carvedilol, a α/β‐antagonist with antioxidant properties. The 6‐min. walk test, the left ventricular ejection fraction, heart rate, plasma norepinephrine and malondialdehyde, a stress oxidative marker, concentrations were evaluated at baseline and after treatment for 6 months with carvedilol in 33 stable chronic heart failure patients with the Gln27→Gluβ2‐adrenergic receptor polymorphism. Carvedilol significantly increased the left ventricular ejection fraction, while decreasing the heart rate and malondialdehyde plasma concentrations in chronic heart failure patients with the Glu27β2‐adrenergic receptor allele. There were however, no significant changes in patients with the Gln27β2‐adrenergic receptor variant. |
| |
| Keywords: | |
|
|
